DK2384192T3 - Biologisk oliesammensætning, formuleringer, der omfatter oliesammensætningen, og anvendelse deraf til at forebygge eller behandle kardiovaskulær sygdom - Google Patents
Biologisk oliesammensætning, formuleringer, der omfatter oliesammensætningen, og anvendelse deraf til at forebygge eller behandle kardiovaskulær sygdom Download PDFInfo
- Publication number
- DK2384192T3 DK2384192T3 DK10700011.9T DK10700011T DK2384192T3 DK 2384192 T3 DK2384192 T3 DK 2384192T3 DK 10700011 T DK10700011 T DK 10700011T DK 2384192 T3 DK2384192 T3 DK 2384192T3
- Authority
- DK
- Denmark
- Prior art keywords
- oil composition
- composition
- epa
- dha
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 83
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 50
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 50
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 47
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 47
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 45
- 241000239250 Copepoda Species 0.000 claims abstract description 40
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 241000239266 Calanus finmarchicus Species 0.000 claims abstract description 9
- 239000004164 Wax ester Substances 0.000 claims description 24
- 235000019386 wax ester Nutrition 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 17
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 16
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000239263 Calanus Species 0.000 claims description 6
- 150000002191 fatty alcohols Chemical class 0.000 claims description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 5
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 5
- 229940022405 astaxanthin Drugs 0.000 claims description 5
- 239000001168 astaxanthin Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000015961 tonic Nutrition 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 229960000716 tonics Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 abstract description 93
- 230000000694 effects Effects 0.000 abstract description 20
- 208000029078 coronary artery disease Diseases 0.000 abstract description 13
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 abstract description 3
- 235000019198 oils Nutrition 0.000 description 89
- 235000005911 diet Nutrition 0.000 description 27
- 230000037213 diet Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000000709 aorta Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000007505 plaque formation Effects 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 235000012716 cod liver oil Nutrition 0.000 description 5
- 239000003026 cod liver oil Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 229940106134 krill oil Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000239370 Euphausia superba Species 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000283153 Cetacea Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000276438 Gadus morhua Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000489 anti-atherogenic effect Effects 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 101150106671 COMT gene Proteins 0.000 description 1
- 241000186240 Calanus hyperboreus Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 241000276446 Gadiformes Species 0.000 description 1
- 241000204888 Geobacter sp. Species 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- -1 thromboxans Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Biologisk oliesammensætning, der omfatter 20-100 vægt-% voksestere, fortrinsvis 70-100 vægt-% voksestere, og hvor sammensætningen omfatter 5-20 vægt-% stearidonsyre (SDA), til anvendelse som et medikament til forebyggelse eller behandling af en kardiovaskulær sygdom.
2. Biologisk oliesammensætning ifølge krav 1 til anvendelse som et medikament til forebyggelse eller behandling af aterosklerose.
3. Biologisk sammensætning ifølge krav 1 til anvendelse som et medikament til forebyggelse eller behandling af hyperkolesterolæmi.
4. Biologisk sammensætning ifølge krav 1 til anvendelse som medikament til forebyggelse eller behandling af forhøjede kolesterolniveauer i blodet.
5. Biologisk oliesammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor sammensætningen omfatter 3-15 vægt-% eicosapentaensyre (EPA) og 2-10 vægt-% docosahexaensyre (DHA).
6. Biologisk oliesammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor sammensætningen omfatter fedtalkoholer og SDA, DHA og EPA som monoestere med fedtalkoholer.
7. Biologisk oliesammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor sammensætningen indeholder 1000-4000 ppm astaxanthin.
8. Biologisk oliesammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor sammensætningen er isoleret fra en copepod.
9. Biologisk oliesammensætning til anvendelse ifølge krav 8, hvor copepoden er af arten Calanus.
10. Biologisk oliesammensætning til anvendelse ifølge krav 9, hvor copepoden er af arten Calanus finmarchicus.
11. Farmaceutisk formulering, der omfatter en biologisk oliesammensætning ifølge et hvilket som helst af kravene 1-10 til anvendelse i terapi.
12. Formulering til anvendelse ifølge krav 11, der er tilvejebragt i kapsler, tabletter, emulsioner eller tonika.
13. Formulering til anvendelse ifølge krav 12, der omfatter ét eller flere farmaceutisk acceptable additiver udvalgt fra gruppen bestående af adjuvans, antioxidanter, emulgeringsmidler, overfladeaktive midler og bærere.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20090033 | 2009-01-05 | ||
| PCT/NO2010/000002 WO2010077152A1 (en) | 2009-01-05 | 2010-01-04 | Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2384192T3 true DK2384192T3 (da) | 2018-01-08 |
Family
ID=41785909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10700011.9T DK2384192T3 (da) | 2009-01-05 | 2010-01-04 | Biologisk oliesammensætning, formuleringer, der omfatter oliesammensætningen, og anvendelse deraf til at forebygge eller behandle kardiovaskulær sygdom |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110251276A1 (da) |
| EP (1) | EP2384192B1 (da) |
| JP (2) | JP2012514596A (da) |
| CN (1) | CN102271670A (da) |
| CA (1) | CA2750153C (da) |
| DK (1) | DK2384192T3 (da) |
| ES (1) | ES2653940T3 (da) |
| NO (1) | NO2384192T3 (da) |
| RU (1) | RU2563995C2 (da) |
| WO (1) | WO2010077152A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010143977A1 (en) * | 2009-06-12 | 2010-12-16 | Calanus As | Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders |
| CN106999460B (zh) * | 2014-08-12 | 2021-07-09 | 信息化学和应用神经研究所 | 用于抑制海虱附着于鱼上的棕榈油酸 |
| IT201700054543A1 (it) | 2017-05-19 | 2018-11-19 | Gleaner Srls | Preparato come fonte di Omega-3 |
| CN107802643B (zh) * | 2017-12-12 | 2020-03-27 | 江苏扬新生物医药有限公司 | 一种含有虾青素的软胶囊 |
| JP2020061956A (ja) * | 2018-10-16 | 2020-04-23 | 日本水産株式会社 | 血清中ｔｍａｏ低減用組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
| JPH10155459A (ja) * | 1996-11-27 | 1998-06-16 | Suntory Ltd | アスタキサンチン含有飲食物 |
| IT1292126B1 (it) * | 1997-06-11 | 1999-01-25 | Guido Galliani | Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso |
| US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
| CA2251265A1 (en) | 1998-10-21 | 2000-04-21 | Universite De Sherbrooke | Process for lipid extraction of aquatic animal tissues producing a dehydrated residue |
| GB0016452D0 (en) | 2000-07-04 | 2000-08-23 | Kilgowan Limited | Vitamin K and essential fatty acids |
| WO2002092779A2 (en) * | 2001-05-17 | 2002-11-21 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
| US6500468B1 (en) * | 2002-01-03 | 2002-12-31 | Farlong Pharmaceutical, Inc. | Panax notoginsenoside composition |
| US20060127449A1 (en) * | 2003-01-28 | 2006-06-15 | Hargrove James L | Method and composition for lowering cholesterol |
| US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
| AU2005322015B2 (en) * | 2004-12-29 | 2010-02-25 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
| CN101437508A (zh) * | 2006-03-03 | 2009-05-20 | 孟山都技术有限公司 | 用于改善心血管健康的十八碳四烯酸 |
| MX2009004337A (es) | 2006-11-01 | 2009-05-22 | Pronova Biopharma Norge As | Compuestos lipidos omega-3. |
| EP2144618B1 (en) * | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
-
2010
- 2010-01-04 DK DK10700011.9T patent/DK2384192T3/da active
- 2010-01-04 ES ES10700011.9T patent/ES2653940T3/es active Active
- 2010-01-04 WO PCT/NO2010/000002 patent/WO2010077152A1/en active Application Filing
- 2010-01-04 CN CN2010800040437A patent/CN102271670A/zh active Pending
- 2010-01-04 RU RU2011130700/15A patent/RU2563995C2/ru active
- 2010-01-04 EP EP10700011.9A patent/EP2384192B1/en active Active
- 2010-01-04 JP JP2011544395A patent/JP2012514596A/ja active Pending
- 2010-01-04 CA CA2750153A patent/CA2750153C/en active Active
- 2010-01-04 NO NO10700011A patent/NO2384192T3/no unknown
- 2010-01-04 US US13/130,585 patent/US20110251276A1/en not_active Abandoned
-
2014
- 2014-06-16 US US14/305,011 patent/US9820958B2/en active Active
-
2015
- 2015-04-30 JP JP2015093609A patent/JP5932111B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010077152A1 (en) | 2010-07-08 |
| CA2750153A1 (en) | 2010-07-08 |
| CN102271670A (zh) | 2011-12-07 |
| EP2384192A1 (en) | 2011-11-09 |
| US9820958B2 (en) | 2017-11-21 |
| JP2015180640A (ja) | 2015-10-15 |
| CA2750153C (en) | 2016-11-08 |
| RU2563995C2 (ru) | 2015-09-27 |
| ES2653940T3 (es) | 2018-02-09 |
| JP2012514596A (ja) | 2012-06-28 |
| US20140302128A1 (en) | 2014-10-09 |
| EP2384192B1 (en) | 2017-10-25 |
| JP5932111B2 (ja) | 2016-06-08 |
| RU2011130700A (ru) | 2013-02-10 |
| US20110251276A1 (en) | 2011-10-13 |
| NO2384192T3 (da) | 2018-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11865143B2 (en) | Bioeffective krill oil compositions | |
| US20080113046A1 (en) | Use of Omega-3 Fatty Acid(s) for Treating Hypercholesterolemia Caused by Anti-Retroviral Treatment of Hiv-Infected Patients | |
| US9820958B2 (en) | Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease | |
| EP2027864B1 (en) | Composition for improvement of lipid metabolism | |
| KR20210099631A (ko) | 초장쇄 지방산 조성물 | |
| Bowen-Forbes et al. | Fats | |
| US9808437B2 (en) | Monounsaturated fatty acid compositions and use for treating atherosclerosis | |
| US10485779B2 (en) | Oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders | |
| AU2012101335B4 (en) | Processes and products thereof |